Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 84,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Urinary Bladder Neoplasms
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Head and Neck Cancer, Pain, Postoperative
Interventions: Pregabalin 150mg, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Adrenal Insufficiency
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post-Traumatic Stress Disorder in Adolescence
Interventions: Prism; Device
Lead sponsor: GrayMatters Health Ltd.; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
Interventions: Transcranial Direct Current Stimulation, Cognitive Remediation (CR); Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer
Interventions: Exercise Program, Telephone-based intervention, Counseling intervention, Questionnaire administration, Relaxation Program; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Interventions: Ibrutinib; Drug
Lead sponsor: Pharmacyclics Switzerland GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 34
States / cities: Burbank, California • Duarte, California • La Jolla, California + 27 more

Conditions: Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer, Small Cell Lung Cancer Extensive Stage
Interventions: Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Childhood Cancer
Interventions: One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Osteoporosis
Interventions: ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1997
U.S. locations: 15
States / cities: Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more

Conditions: PTSD
Interventions: AboutFace Website; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Glioma
Interventions: Retreatment Rhenium Liposome; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions: Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil; Drug · Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 65 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Kidney Diseases
Interventions: Mindfulness-based stress reduction (MBSR), Health enhancement program (HEP), Transcutaneous Vagus Nerve Stimulation (tVNS), Sham-transcutaneous Vagus Nerve Stimulation (tVNS); Behavioral · Device
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Distal Radius Fracture
Interventions: Opiate Sparing, Opiate Based; Other
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Binge Eating Disorder
Interventions: Integrative Response Therapy, Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphocytic Leukemia
Interventions: alemtuzumab, everolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine; Drug · Procedure · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: Dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chula Vista, California • Escondido, California • Renton, Washington

Conditions: Covid19
Interventions: Bucillamine, Placebo; Drug
Lead sponsor: Revive Therapeutics, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 46
States / cities: Cullman, Alabama • Huntsville, Alabama • Phoenix, Arizona + 38 more

Conditions: Prostate Specific Antigens, Prostate Neoplasms
Interventions: T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PF-08046876, Pembrolizumab, Cisplatin, Carboplatin; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 11 more

Conditions: Osteoarthritis, Knee
Interventions: XT-150; Biological
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Napa, California

Search by objective public record fields.

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder

Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery

Adrenal Function in Critical Illness

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia

Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

Pilot Evaluation of AboutFace: Novel Peer Education Resource for Veterans

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

Mindfulness in Chronic Kidney Disease

Opiate Sparing Protocol Randomized Controlled Trial in Open Distal Radius Fracture Repair

Guided Self-Help for Binge Eating Disorder

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Bucillamine in Treatment of Patients With COVID-19

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain